

Welcome to our March 2018 newsletter, bringing you a snapshot of our recent and upcoming activities

Haematology and Hepatology join forces at UCLH in new 'shared liver clinic' to benefit patients

When Dr Drasar, Consultant Haematologist and Dr Suri, Consultant Hepatologist at University College of London Hospitals reviewed the needs of patients and their respective clinics, they realised a joint approach could be the perfect path to shared care and expertise.

With this in mind, in the summer of 2017, the two established a new shared 'Liver Clinic' at UCLH (under the auspices of the Red Cell Centre and Prof John Porter). Patients are provided with a single point of care for all hepatology and haematology medical consultations, expert advice, and treatment plans.

The established shared clinic is providing an easy point of access for patients, who can now attend a single combined clinical consultation that best suits their needs. The combined consultation visits also enable Dr Suri and Dr Drasar to share knowledge. The combination of their particular expertise and research interests in both red cell haematology and iron disorders, and their effect on the liver is contributing to the optimisation of treatment plans.

An excellent example

Multidisciplinary approaches to patient management is nothing new, with shared care and multidisciplinary teams now common place in hospitals. However 'shared clinics' between haematology and hepatology are less common, and the new Liver Clinic is an excellent example of how this can work wonders for care delivery – especially in patients at risk of iron overload where there is natural overlap. The target patients for this clinic include iron overload disorders (including haemochromatosis),

thalassaemia patients, and also patients with sickle cell disorder.

Patients attending the liver clinic can be referred for a FerriScan MRI to assess Liver Iron Concentration as well as a Liver Fat assessment (Hepafat-Scan) at the same time if needed at UCLH. Patients also have the possibility to access other non-invasive diagnostics where required, including assessment of fibrosis alongside other biomarkers, to assist in determining liver function and to assist in optimising the clinical management of conditions.



Dr Emma Drasar



Dr Deepak Suri

Dr Drasar talked about the key advantages of running the joint liver clinic, namely the unique access to a complete assessment of liver damage and aetiology through a novel combination of investigations.

Dr Suri also explained that the patients really appreciate the "one stop" service that they receive with access to both haematology and hepatology services in one visit. Liver disease in these patients is often under recognised, and is increasing in importance; this clinic allows optimal care to be delivered to patients in a convenient way.

Expedited Report Service now available to customers!



Resonance Health will be offering a new **expedited analysis** option for FerriScan reports for customers requiring 1 business day service.

FerriScan analysis is currently provided within a targeted turnaround time of 48 hours (2 business days) but in response to customer requests, Resonance Health is now able to offer 1 day expedited reporting for a small additional cost. This service will be available immediately to all of our global customers. For those customers with access to reimbursement, please check whether the expedited service fee is covered by the various providers before commencing use of the service in order to clarify who will be responsible for payment.

To access this expedited service, MRI personnel uploading images can simply select the new 'Patient FerriScan – Expedite (24h turnaround)' option under 'Billing Category' (as seen below) when lodging a new job in FAST so that our service team are aware of the need for the quicker turnaround.



This option can be restricted for use to specific users only (if requested) by an authorized FAST contact. Please contact Resonance Support if you wish to allocate this feature to individual users of your site.

If you have any further questions please contact support@resonancehealth.com for additional support.

New MRI Liver Inflammation screening tool launched at NASH Global Engage Congress, London



Photo Caption: Melanie Baxter, Resonance Health and Dr Deepak Suri showcase Resonance Health's technology at NASH Global Engage Conference.

Dr Deepak Suri, Consultant Hepatologist from Whittington Hospital and University College London, presented evidence and applications of a suite of MRI tools for liver assessment from Resonance Health at the recent NASH Global Congress in London. These included a new inflammation screening tool, NASHscan for investigational use, which sparked much interest amongst delegates.

The 2 day Conference in late February featured 40 expert led presentations and attracted around 200 international experts working in the areas of non-alcoholic fatty liver and non-alcoholic steatohepatitis. Resonance Health's Marketing Director Melanie Baxter and Research Consultant Dr Susanna Katay-Davies participated in various roundtable discussions and networking sessions as part of the dynamic program.

Melanie Baxter said; "The congress provided an excellent opportunity to present new data on Resonance's inflammation screening tool and to share results of the application of our FerriScan and HepaFat-Scan technologies in a recent study on unexplained hyperferritinemia. It was very well received and we met many new senior contacts from industry, hospitals and universities who are keen to collaborate with us to advance healthcare in this challenging disease indication."

Upcoming Conference Schedule

Resonance Health is busy preparing for some key conferences and events which provide the ideal opportunity for our team to gain closer customer, clinical and industry engagement. We look forward to meeting with you all at the various conference events throughout the year and sharing our exciting innovation pipeline and new clinical data.



European Association for the Study of the Liver Annual Meeting (EASL), France

11 – 15 April 2018

Resonance Health's Chief Scientific Officer, Prof. St Pierre, and Clinical Research Manager, Dr Sherif Boulos, will be attending this year's EASL conference and associated Liver Forum to meet with customers and collaborators on the ongoing and developing role for our HepaFat-Scan and FerriScan technologies. Our attending team have a busy schedule of meetings over our newly announced NASH measurement tool, with Professor Tim St Pierre presenting new clinical data on this service at the event. [Read more...](#)

58th Annual Scientific Meeting – British Society for Haematology, Liverpool

16 – 18 April 2018

Chief Scientific Officer, Professor Tim St Pierre, and Research Consultant, Dr Susanna Katay-Davies, will be at this year's BSH Annual Scientific Meeting as attending delegates to connect with numerous key opinion leaders and health care professionals. This conference will cover a range of haematological conditions and provide Resonance Health with the opportunity to discuss the latest developments and optimal management of iron overload and further profile our technologies. [Read More...](#)

6th Symposium for Haematology Today, Germany

19 – 21 April 2018

The 'Hamatologie Heute' event continues to gather much pace and is now in its 6th Symposium. The 3 day event organized by Prof Cario Holger and Dr Stephan Lobitz is held in Ulm this year and will attract over 200 participants from Europe, with international experts contributing to the impressive scientific program. Discussions will include new developments and therapeutic strategies for MDS, Sickle Cell Disease and other blood disorders. Resonance Health is delighted to continue supporting this important event with our German representative Tilo Stolzke in attendance to meet with key opinion leaders in the field and further discussions to expand access to our technologies across Germany and beyond. [Read more...](#)

UK Haemoglobinopathy Forum: 45th Academic Meeting, London

09 May 2018

UKFHD's Academic Meeting allows experts from across the globe to come together to discuss and collaborate on the latest in haemoglobinopathy research. This year Resonance Health is pleased to team up with Agios Pharmaceuticals with a shared information stand. The Resonance Health team will be represented by our UK Research Consultant Dr Susanna Katay-Davies who will be in attendance to discuss the role of FerriScan in the treatment and monitoring of patients. [Read more...](#)

European Hematology Association (EHA) 23rd Congress, Sweden

14 – 17 June 2018

The EHA congress is Europe's flagship haematology event and provides extensive updates on patient care, research, and education in all specializations of hematology. Resonance Health's Prof Tim St Pierre, and Susanna Katay-Davies will be attending this important conference to share new knowledge, hold key strategic meetings with various pharmaceutical companies, and further promote uptake of the FerriScan and HepaFat-Scan technologies. Professor Tim St Pierre is also expected to present and abstract showcasing new FerriSmart Artificial Intelligence information during the 4-day event. Please email Tim St Pierre directly at tims@resonancehealth.com if you wish to organise a meeting. [Read more...](#)

Important Update to Phantom Reverification Process – Changes Ahead for Easier Certification!

At Resonance Health we strive to incorporate customer feedback and are delighted to report we have made significant steps towards streamlining the FerriScan Phantom verification process to improve customer experience.

As from the 31st of March, Resonance Health will no longer require yearly reverification from our FerriScan Phantom Packs on your individual MRI scanners.

Using over 13 years of scanned FerriScan Phantom and patient data, we can now monitor data from scans regularly to see whether it meets our quality system requirements. This internal process will now replace annual routine phantom scans.

To maintain the high standard of the FerriScan service, Resonance Health still requires Phantom verification from customers in the following situations:

- If you are a new hospital centre being set up for the first time;
- If your MRI machines have recently gone through significant software or hardware upgrades, such as operating system upgrades and/or gradient system changes;
- Your site has recently purchased a new MRI scanner/s that will use the FerriScan service;
- You are using FerriScan services within a clinical trial.

Please be aware that from time to time Resonance Health may request that an MRI centre performs an additional phantom reverification. Resonance has stringent procedures around incoming quality control, and from time to time, there may be an identifiable problem with the data being acquired that necessitates phantom scan.

All customers are welcome to continue an optional annual Phantom reverification at their hospital centre if desired. To request continuation of this service, please contact support at support@resonancehealth.com to discuss further.

We thank you for your continued support of the FerriScan service.

R&D Update – Speed Scanning on the horizon for FerriScan!

The Resonance Health R&D team have commenced research on a shortened acquisition time for the FerriScan protocol which currently takes approximately 9 minutes. The first FerriScan performed in 2004 required almost 20 to 30 minutes of data acquisition, so the 9 minute scan seems short by comparison – but for very busy MRI departments where demand for time on the scanner bed is high, every second counts. Initial data is being gathered as part of our ‘Dragon 2 study’ with colleagues at Bach Mai hospital in Vietnam in an exciting project to reduce the scan time significantly from 9 minutes to a 2 minute FerriScan acquisition.

Dr Wenjie Pang, Resonance Health’s Technical Manager commented: ‘We are hoping to develop a new FerriScan acquisition protocol that will not only enable MRI centres to increase the patient scans they perform per hour, but ultimately reduce the cost per patient as less scanner time will be required. The shortened scan time may also provide improved image quality for our internal analysis which will improve efficiency for our data analysis and quality assurance processes. The new protocol requires rigorous testing to ensure our sensitivity and specificity is maintained but initial results are looking very promising indeed.’

We look forward to updating our customers on this exciting development as data becomes available.

Resonance Health hires new sales specialists

Resonance Health is delighted to welcome 2 new sales specialists to the Company in the regions of Canada and Pakistan for the first time.

The Canadian sales specialist will help facilitate further uptake of the FerriScan service across Canada after FerriScan was accepted for reimbursement in all Canadian provinces as an out-of-country medical service.

Meanwhile, our specialist in Pakistan will work closely with haematologists in Pakistan to build awareness of Resonance Health’s products and to promote uptake in this country with high thalassemia rates.